An exciting new development is the production of a much more potent form of anti-IgE, QGE031 (Novartis), which is at least 12 times more potent than omalizumab for the treatment of IgE-driven diseases where a significant unmet need exists such as severe uncontrolled asthma, atopic dermatitis and food allergies [26]. This evidence concerns the gene IGHE and asthma.